Antiangiogenic agents combined with chemotherapy in the first-line treatment of advanced XXXX : overall and histology subgroup-specific meta-analysis.

@entity1 @entity644 @entity101 @entity882 @entity548 @entity5 @entity1910 @entity294 @entity1149 @entity1295 @entity448 @entity1398 @entity10 @entity1349
AIM: This study investigated the overall and histology subtype-specific results of antiangiogenic agents combined with chemotherapy versus chemotherapy alone for the first-line treatment of advanced @entity1149 ( @entity1149 ). METHODS: Literature retrieval, trial selection, data collection, and statistical analysis were performed according to the Cochrane Handbook. The outcome measures were @entity5 response rate, @entity1349 ( @entity1349 ), @entity1349 ( @entity1349 ), and adverse effects. RESULTS: 13 randomized controlled trials comprising 5,451 @entity1 were included. The meta-analysis showed a higher response rate (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.53-0.74) and a significantly prolonged @entity1349 (hazard ratio (HR) 0.75, 95% CI 0.66-0.85) and @entity1349 (HR 0.92, 95% CI 0.86-0.98) in the groups combining antiangiogenic agents with chemotherapy versus the chemotherapy alone groups. In the histology subgroup analysis, treatment with antiangiogenic agents plus chemotherapy significantly improved the RR, @entity1349 , and @entity1349 as compared with the chemotherapy groups in @entity1 with nonsquamous @entity1149 , but not in those with squamous @entity1149 . The risk of grade 3/4 @entity882 , @entity101 , @entity548 , @entity644 , @entity1910 , @entity294 , @entity1295 , @entity10 , @entity448 , and @entity1398 was significantly increased in the antiangiogenic agent combination groups as compared with the chemotherapy groups. CONCLUSION: The use of antiangiogenic agents in addition to chemotherapy is a valid option for the first-line treatment of advanced @entity1149 . The benefit is restricted to @entity1 with @entity5 .    2014 S. Karger AG, Freiburg.
